Last reviewed · How we verify
CX157
At a glance
| Generic name | CX157 |
|---|---|
| Sponsor | CeNeRx BioPharma Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression (PHASE2)
- Oral Tyramine Pressor Response Study of CX157 Tablets in Healthy Male Volunteers (PHASE1)
- A Study of CX157 (TriRima) for the Treatment of Depression (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CX157 CI brief — competitive landscape report
- CX157 updates RSS · CI watch RSS
- CeNeRx BioPharma Inc. portfolio CI